About us
Yi Chen, PhD
CSO
Specialized in rational drug design and preclinical development;
Led the drug design and preclinical development of 5 clinical compounds
EDO-S101 dual-targeting DNA and HDAC;
LP-108, a selective and potent Bcl-2 inhibitor;
LP-118, a newest-generation selective Bcl-2 inhibitor;
LP-128, a highly potent HBsAg inhibitor for HBV treatment ;
LP-168, a newest generation inhibitor of a validated pathway.